Home/Pipeline/Alpha-synuclein PET Tracer

Alpha-synuclein PET Tracer

Parkinson's Disease

Phase 1Active

Key Facts

Indication

Parkinson's Disease

Phase

Phase 1

Status

Active

Company

AC Immune

About AC Immune

Founded in 2003 and publicly listed on NASDAQ, AC Immune is a global leader in developing precision diagnostics and therapeutics for neurodegenerative diseases. Its strategy is validated by high-value partnerships with pharmaceutical giants like Takeda, Eli Lilly, and Janssen, which have generated over CHF 450 million in funding. The company is advancing a broad pipeline focused on pathological proteins such as Abeta, Tau, alpha-synuclein, and TDP-43, aiming to slow or prevent disease progression.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Tauopathies Synucleinopathies TDP-43 Proteinopathies

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
ABBV-951	AbbVie	Phase 3	Active
UCB0107	UCB	Phase 1	Active
Stalevo	Orion Corporation	Approved	Commercial
Comtan/Comtess	Orion Corporation	Approved	Commercial
CHRONOS-PD Platform	Grifols	Research	Active
GT-001 (Gene Therapy)	Sumitomo Pharma	Phase 1/2	Active
CREXONT (Carbidopa/Levodopa)	Amneal Pharmaceuticals	Approved	Launched
BIIB122/DNL151	Denali Therapeutics	Phase 3	Active (LIGHTHOUSE study)
ABBV-0805	BioArctic AB	Phase 1	Completed (Partnered with AbbVie)
BAN1202	BioArctic AB	Preclinical	Proprietary program
ARV-102	Arvinas	Phase 1	Active - >50% LRRK2 degradation in CSF reported
AAV-GAD	MeiraGTx	Preclinical/Phase 1	Development ongoing